Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective review

被引：0

作者：

Sood, Siddhartha ^{[1
]}

Rimke, Alexander ^{[2
]}

Rankin, Brian D. ^{[3
]}

Abduelmula, Abrahim ^{[4
]}

Georgakopoulos, Jorge R. ^{[4
]}

Maliyar, Khalad ^{[4
]}

Bagit, Ahmed ^{[1
]}

Leung, Fernejoy ^{[5
]}

Devani, Alim R. ^{[2
,5
,6
]}

Vender, Ronald ^{[2
,7
,8
,9
]}

Yeung, Jensen ^{[4
,6
,10
,11
]}

Prajapati, Vimal H. ^{[2
,3
,5
,12
,13
]}

机构：

[1] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada

[2] Dermatol Res Inst, Suite 310,8500 Blackfoot Trail SE, Calgary, AB T2J 7E1, Canada

[3] Univ Calgary, Dept Med, Div Dermatol, Calgary, AB, Canada

[4] Univ Toronto, Dept Med, Div Dermatol, Toronto, ON, Canada

[5] Skin Hlth & Wellness Ctr, Calgary, AB, Canada

[6] Prob Med Res, Waterloo, ON, Canada

[7] McMaster Univ, Div Dermatol, Hamilton, ON, Canada

[8] Dermatrials Res Inc, Hamilton, ON, Canada

[9] Venderm Consulting, Hamilton, ON, Canada

[10] Womens Coll Hosp, Dept Med, Div Dermatol, Toronto, ON, Canada

[11] Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, Toronto, ON, Canada

[12] Univ Calgary, Dept Pediat, Sect Community Pediat, Calgary, AB, Canada

[13] Univ Calgary, Dept Pediat, Sect Pediat Rheumatol, Calgary, AB, Canada

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2025年 / 92卷 / 05期

关键词：

bimekizumab; biologic; biologic switch; intra-class; psoriasis; real-world experience; MODERATE; EFFICACY; SAFETY;

D O I：

10.1016/j.jaad.2024.12.034

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

[No abstract available]

引用

页码：1093 / 1095

页数：3

共 5 条

[1]

Gordon KB, 2021, LANCET, V397, P475, DOI 10.1016/S0140-6736(21)00126-4

[2] Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials [J].

Kokolakis, Georgios ;

Warren, Richard B. ;

Strober, Bruce ;

Blauvelt, Andrew ;

Puig, Luis ;

Morita, Akimichi ;

Gooderham, Melinda ;

Koerber, Andreas ;

Vanvoorden, Veerle ;

Wang, Maggie ;

de Cuyper, Dirk ;

Madden, Cynthia ;

Gomez, Natalie Nunez ;

Lebwohl, Mark .

BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (03) :330-340

[3] Bimekizumab versus Secukinumab in Plaque Psoriasis [J].

Reich, Kristian ;

Warren, Richard B. ;

Lebwohl, Mark ;

Gooderham, Melinda ;

Strober, Bruce ;

Langley, Richard G. ;

Paul, Carle ;

De Cuyper, Dirk ;

Vanvoorden, Veerle ;

Madden, Cynthia ;

Cioffi, Christopher ;

Peterson, Luke ;

Blauvelt, Andrew .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) :142-152

[4] Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis [J].

Reis, Joel ;

Vender, Ron ;

Torres, Tiago .

BIODRUGS, 2019, 33 (04) :391-399

[5] Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors [J].

Yeung, Jensen ;

Vender, Ron ;

Turchin, Irina ;

Shukla, Rahul ;

Maari, Catherine ;

Hong, Chih-ho ;

Barakat, Maxime ;

Lansang, Perla .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (04) :1169-1171

← 1 →